Pharmafile Logo
Pharmafocus logo
Advanced Search

Amgen

Showing 15 posts of 216 posts found.

Amgen scraps pancreatic cancer drug

August 9, 2012
Research and Development, Sales and Marketing Amgen, GAMMA, Ganitumab, pancreatic

Biotech company Amgen has abandoned its late-stage trial of a new drug for one of the most hard-to-treat of all …

News

Lipitor fallout prompts Pfizer to cut Irish workforce

June 7, 2012
Manufacturing and Production Amgen, Ireland, Lipitor, Pfizer, cuts, patent loss

Falling demand for blockbuster cholesterol drug Lipitor has prompted Pfizer to cut staff levels at two manufacturing facilities in Ireland. …

News

Sanofi/Regeneron cholesterol drug reaches Phase III

May 29, 2012
Research and Development, Sales and Marketing Amgen, PCKS9, Regeneron, SAR236553, Sanofi

Sanofi and Regeneron’s anti-cholesterol drug has impressed in a mid-stage trial, and will now progress into Phase III.  The firms’ …

News
Amgen

Amgen to acquire kidney disease specialist for $315m

April 11, 2012
Sales and Marketing Amgen, KAI Pharmaceuticals

Amgen will acquire KAI Pharmaceuticals for $315 million to bolster its late-stage pipeline. The deal, which should be completed within …

News

AstraZeneca signs respiratory pact with Amgen

April 5, 2012
Research and Development Amgen, AstraZeneca, MedImmune, respiratory

AstraZeneca has bought its way into Amgen’s inflammation portfolio with a $50 million upfront payment to co-develop and commercialise five …

News
NICE image

NICE recommends Xgeva for bone metastasis

March 29, 2012
Sales and Marketing Amgen, NICE, Xgeva, Zytiga, denosumab, prostate cancer

NICE has issued draft guidance recommending Amgen’s Xgeva (denosumab) for certain groups of cancer patients whose disease has spread to …

News

Approval for Affymax and Takeda’s anaemia treatment

March 29, 2012
Sales and Marketing Affymax, Amgen, ESA, Epogen, Takeda, omontys

The first rival treatment to Amgen’s portfolio of anaemia drugs has been approved in the US.Omontys (peginesatide) has been developed …

News
Amgen picture

Sanofi sets up cholesterol drug showdown with Amgen

March 27, 2012
Research and Development, Sales and Marketing Amgen, BMS, LDL, Lipitor, Merck, Regeneron, Sanofi

Sanofi and Amgen have posted results for their new injectable cholesterol drugs within 24 hours of each other.  Both drugs …

News

Novartis starts late-stage biosimilar trials for Amgen drugs

January 19, 2012
Research and Development, Sales and Marketing Amgen, Neulasta, Neupogen, Novartis

Novartis has begun Phase III biosimilar trials to copycat two of Amgen’s neutropenia drugs. The studies, which are being undertaken …

News

Amgen’s chief executive and chairman Kevin Sharer to retire

December 16, 2011
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Amgen

Kevin Sharer, Amgen’s chairman and chief executive, has announced his retirement next year, leading the way for Robert Bradway to …

Appointment

Amgen poaches Tony Hooper from Bristol-Myers Squibb

October 21, 2011
Medical Communications Amgen, BMS

Amgen has appointed Tony Hooper as the new executive vice president of global commercial operations. Hooper, 56, joins Amgen after …

Appointment

Amgen bone cancer drug Xgeva approved in Europe

July 18, 2011
Sales and Marketing Amgen, Prolia, Xgeva, denosumab

Amgen’s bone cancer drug Xgeva (denosumab) has been approved in Europe to prevent serious bone problems in cancer patients. Already …

News
Amgen

Amgen collaborates on cancer antibody research

July 13, 2011
Research and Development Amgen, Cancer, TGF-beta monoclonal antibody, research and development news

Amgen has teamed up with German biotech Micromet to develop tumour-destroying antibodies in a two-year deal that could net Micromet …

News

UCB and Amgen’s osteoporosis drug shows promise

April 21, 2011
Research and Development Amgen, UCB, osteoporosis

Amgen and UCB have announced strong results from a phase II study of their new postmenopausal osteoporosis treatment. Most existing …

News
Amgen

Amgen’s novel lung cancer drug disappoints in phase III

April 1, 2011
Research and Development Amgen, Millennium, NSCLC, Takeda, motesanib, non-small cell lung cancer

Amgen’s lung cancer drug motesanib has not meet its primary endpoint in a phase III study. The drug, developed in …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025